Table 3.
Lung CFU counts assessed during treatment and relapse, assessed 3 months after treatment completion in experiment 1
| Group | Drug regimen | Mean (±SD) log10 CFU count ata: |
Proportion (%) relapsing after treatment for: |
|||||
|---|---|---|---|---|---|---|---|---|
| D−13 | D0 | M1 | M2 | 2 mos | 3 mos | 4 mos | ||
| Untreated | 3.54 ± 0.52 | 7.27 ± 0.44 | ND | ND | ND | ND | ND | |
| A | RIF + PZA + INHb | 4.73 ± 0.29 | 3.04 ± 0.27 | ND | 15/15 (100) | 9/14 (64) | ||
| B | TMC + PNU + CFZ + PA-824 | 3.48 ± 0.57 | 0.37 ± 0.75 | 14/15 (93) | 2/15 (13) | 1/15 (7) | ||
| C | TMC + PNU + CFZ | 3.37 ± 0.74 | 0 | 13/15 (87) | 4/15 (27) | 1/14 (7) | ||
| D | TMC + PNU + PA-824 | 3.99 ± 0.89 | 0.97 ± 1.18 | 15/15 (100) | 6/14 (43) | 0/15 (0) | ||
| E | TMC + CFZ + PA-824 | 4.39 ± 0.51 | 1.55 ± 1.14 | 15/15 (100) | 9/15 (60) | 5/15 (33) | ||
| F | PNU + CFZ + PA-824 | 4.47 ± 0.39 | 0.82 ± 1.64 | 15/15 (100) | 15/15 (100) | 15/15 (100) | ||
a
Time points are shown in days (e.g., D−13, day −13; D0, day 0) or months (e.g., M1, 1 month) of treatment. ND, not done.
b
For the RIF + PZA + INH regimen, PZA was given for the first 2 months only.